Mortality in the first 2 years among infants born to human immunodeficiency virus-infected women in Harare, Zimbabwe.
about
Vaccination for preventing postherpetic neuralgiaVaccination for preventing postherpetic neuralgiaEfficacy of live zoster vaccine in preventing zoster and postherpetic neuralgiaReducing the burden of Herpes Zoster in ItalyVaccination against Herpes Zoster and Postherpetic NeuralgiaFrom HIV Abandonment to Adoption: Case study of New Life Home for abandoned babies, KenyaSevere morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, Côte d'Ivoire, 2004-2009.Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.Effect of maternal HIV status on infant mortality: evidence from a 9-month follow-up of mothers and their infants in Zimbabwe.Evaluation of the prototype Roche DNA amplification kit incorporating the new SSK145 and SKCC1B primers in detection of human immunodeficiency virus type 1 DNA in Zimbabwe.The cancer patient with chronic pain due to herpes zoster.Herpes zoster in older adults.Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries.Review: The neurobiology of varicella zoster virus infection.Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.Prevention of shingles by varicella zoster virus vaccination.Fetal immune activation to malaria antigens enhances susceptibility to in vitro HIV infection in cord blood mononuclear cellsZoster vaccine live.Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination.Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.Shingles vaccine.Preventing and managing herpes zoster: key actions to foster healthy aging.Outcome of HIV exposed infants: experience of a regional pediatric center for HIV in North India.Highly active anti-retroviral therapy in the prevention of mother-to-child transmission of HIV in rural Zimbabwe during the socio-economic crisis.Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen.Studies on shingles, is the virus ordinary chickenpox virus?Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster.Varicella and herpes zoster vaccine development: lessons learned.Responder cell frequency estimation and binomial three-level nonlinear mixed effects model in limiting dilution assays.
P2860
Q24235822-23950580-A805-41F7-9942-9BD4EDE9C276Q24241959-B39BBF8A-0676-4847-B976-841960C41E3EQ24606799-0766E077-E73A-4442-9706-A6780793FDB8Q26998625-0CCCEF8B-90D0-4E99-9BFD-FEB0A7C2DA45Q28276808-D10BC017-D8AD-4C49-9EE7-690A285F454CQ30404688-390AB411-7A94-4C91-85A2-0DC5ECEE6236Q31020587-1CFD3C2B-EE4C-4A29-8A79-488483C37020Q33585349-0FAEB13F-EFFF-4E44-9FB5-FE32271FA9A5Q33710336-D1077EC0-8035-40B6-A7FB-A9C5019E28EBQ33963536-39D452E2-48E5-48BA-8A44-DFA70ADB775BQ34074618-00FCD35F-F691-4CC4-9D29-74365199F38FQ34228634-45380A1D-9565-4752-B73E-E8ADE204C02EQ34683751-D6698897-15E8-42FB-9B39-6CC030EB5556Q35223289-355A9171-E70E-42FB-A660-007E352076F0Q35667362-E4748FA4-E554-4CB3-A201-C91CED55E4DBQ36118527-57899303-B28D-4D87-ACD0-86884E97C403Q36600317-159C34B4-B8A1-443A-AAD3-D14C070C2A66Q36749601-79BBFA06-3C65-45E8-BF5A-A0927E0AA64CQ36861648-7BB77019-D5FB-4407-AA79-B2E24DFBC417Q37425515-E602BE17-3137-4131-8425-BF0F4E7742EFQ37521902-37ED3C1A-5625-4CD1-8C91-3F79354F966EQ37683770-21AAFC6A-9B1C-4435-9D47-1B506F0EC6C9Q38416454-B66C16E7-B2B6-4C03-9F1C-C0A303210130Q41935131-0CFF6437-41E5-4E3A-B806-3C82C63FEF27Q43530502-B03F5EF9-3125-4CEC-B6C1-303251BA341FQ43613106-891E716C-6CBC-4FE9-9281-4D8FC8FCB855Q44064006-FEB1A06D-318D-4C9E-BF98-AD2A2412EC90Q44568321-D9250E67-F0FF-4D42-B62E-F2DCBAEBBEA6Q47607699-28E2B20D-8A19-49BB-AEE2-2DBC9C0BD101Q52973209-42B78ABD-79FE-4FEC-A3E8-9A01314F8924
P2860
Mortality in the first 2 years among infants born to human immunodeficiency virus-infected women in Harare, Zimbabwe.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Mortality in the first 2 years ...... ted women in Harare, Zimbabwe.
@en
Mortality in the first 2 years ...... ted women in Harare, Zimbabwe.
@nl
type
label
Mortality in the first 2 years ...... ted women in Harare, Zimbabwe.
@en
Mortality in the first 2 years ...... ted women in Harare, Zimbabwe.
@nl
prefLabel
Mortality in the first 2 years ...... ted women in Harare, Zimbabwe.
@en
Mortality in the first 2 years ...... ted women in Harare, Zimbabwe.
@nl
P2093
P356
P1476
Mortality in the first 2 years ...... ted women in Harare, Zimbabwe.
@en
P2093
Katzenstein D
Maldonado Y
P304
P356
10.1086/514264
P407
P577
1998-07-01T00:00:00Z